The Memo: Inmedix Bringing Precision to the Autonomic Nervous System

Under the direction of Co-Founder and CEO Dr. Andrew Holman, Inmedix is advancing a new category of precision diagnostics focused on the autonomic nervous system (ANS), an often overlooked contributor to chronic disease and treatment response variability. Through its FDA-cleared CloudHRV^Ⓡ system, the company is equipping clinicians with a medical-grade, real-time measure of ANS state, enabling a more personalized and data-driven approach to care. Built on decades of clinical research and grounded in rheumatology, Inmedix is positioning ANS measurement as a foundational input in modern medicine, with the potential to reshape how physicians understand and treat complex, chronic conditions.

Origin Story

Inmedix is rooted in Dr. Holman’s decades-long career as a rheumatologist and clinical researcher, where he developed a reputation for tackling some of the most misunderstood conditions in medicine.

“After becoming a physician, I specialized in rheumatology due to its puzzle-solving demands and complex immunology,” Holman said. “On a personal note, I never left a room with a patient crying and maintained relationships with patients for decades. I always believed patients when others didn’t.” 

That commitment became especially important in the treatment of fibromyalgia, a condition long dismissed by parts of the medical community.

“The turning point came when I didn’t give up on fibromyalgia patients at a time when the condition was widely dismissed or misunderstood. For decades, women with fibromyalgia were told their symptoms were ‘all in their head’ or attributed to stress, anxiety, hormonal issues, or simply not a clinician’s problem,” he explained.

Driven to better understand these patients, Holman began exploring how the body’s stress response influences chronic disease treatment. His clinical work led to a key insight: a measurable connection between heart rate variability (HRV) and disruption of the ANS, the system that controls the body’s stress response, including functions such as heart rate and immune activity.

Following three prospective clinical trials and the sale of an international patent portfolio to Boehringer Ingelheim, Holman stepped away from the field. But the implications of his research stayed with him.

“Over the next 10 years, I couldn’t sleep at night knowing I held ANS testing technology with potential application to autoimmune disease,” he said. “This drove me out of retirement to found Inmedix.”

Today, the company is headquartered in Seattle, Washington, with an initial focus on the U.S. market and plans for international expansion through its subsidiary, Inmedix UK.

The Current Landscape

Inmedix is entering a large and underserved clinical landscape where treatment outcomes remain inconsistent and difficult to predict.

More than 15 million patients in the U.S. suffer from autoimmune diseases and fibromyalgia, with 75% failing to respond to current treatments and over $10 billion wasted annually, according to the Inmedix team. These conditions disproportionately affect women, who make up roughly 80% of diagnosed patients.

Despite available treatments, outcomes remain unpredictable. In rheumatoid arthritis (RA) alone, three out of four treatments fail to adequately control the disease.

According to peer-reviewed evidence, a critical variable appears to be missing.

“A prominent missing link appears to be the ANS,” he said. “The ability to precisely measure the ANS has been reported to strongly impact how patients react to RA immunosuppressive treatment.”

The ANS regulates the body’s stress response, influencing immune activity, cardiovascular function, sleep, and metabolism. Excessive ANS sympathetic activity (fight-or-flight) contributes to chronic illness, morbidity, and mortality due to metabolic syndromes, sleep, mood, strain on the heart, and impaired immune function.

Holman points to the ANS as an “invisible factor affecting 60 to 80% of primary care complaints,” highlighting its potential role as a foundational driver across a wide range of diseases.  

Inside the Innovation

Inmedix’s solution centers on its CloudHRV system, an FDA-cleared diagnostic platform that delivers a precise measurement of ANS state using a five-minute ECG.

During an assessment, patients lie supine while ECG leads are applied to the wrists and ankles. The system captures approximately 350 heartbeats over five minutes, transmitting the data to a secure cloud environment where beat-to-beat variability is analyzed through proprietary calculation.

Results are returned to the clinician within seconds, providing immediate, actionable insight for clinical decision-making.

“Clinicians now have an FDA-cleared, precise measure of ANS state at rest, including, for the first time, indices of both the sympathetic and the parasympathetic components,” Holman said. “This advance is analogous to the difference between a basic X-ray and a detailed MRI scan. Precision is key.”

Unlike traditional HRV tools designed to assess damage to the body’s ANS command-and-control functions from brain conditions and other dysfunctions, CloudHRV assesses the ANS as a dynamic regulatory factor. This distinction shifts the focus from diagnosing damage to understanding how underlying physiology may influence disease progression and treatment response.

For clinicians, the system introduces a new layer of data that may help explain why seemingly similar patients respond differently to the same treatment. For patients, it offers the potential to move beyond trial-and-error treatment approaches.

“This could mean faster relief, fewer failed medications, and the validation that their symptoms are real and measurable,” Holman said.

Progress and Milestones

Inmedix has reached the commercial stage following FDA clearance of CloudHRV in January 2025, marking a significant milestone as the first FDA-cleared cloud-based HRV diagnostic of its kind.

The company completed a soft launch across Washington, Oregon, Michigan, and Florida in June 2025, refining its hardware, software, QMS, medical affairs, and compliance infrastructure while validating its SaaS business model.

That model combines an annual system lease with a per-test fee, creating recurring revenue streams aligned with clinical utilization.

To date, Inmedix has raised more than $19 million in seed funding and has already begun generating revenue. The company has completed over 1,500 tests following its soft launch and is experiencing strong early demand, with a waitlist of more than 200 doctors requesting Inmedix’s device for their own practices.

In parallel, Inmedix has established research collaborations with leading institutions, including Johns Hopkins, Spaulding Rehab, and Harvard Medical School's Department of Physical Medicine and Rehabilitation, with additional work planned alongside the Cleveland Clinic.

Looking ahead, the company is raising a Series A to accelerate clinical studies for expanded applications, reach full commercialization in the U.S., advance an 18-study clinical development plan, and achieve positive cash flow in 2026.

Holman’s long-term vision is ambitious but grounded in clinical reality.

“We envision the ANS state with sympathetic and parasympathetic indices to become a standard vital sign measured at every medical visit, as routine as checking blood pressure,” Holman said.

If realized, that vision would position ANS measurement as a core input in precision medicine, with potential applications across a wide range of conditions.

“Essentially, our goal is to understand the patient from a more holistic approach, to understand what outside factors matter in medicine, and to advance from guesswork to precision,” he said.